SMAD7 and melanoma: A neutralizing pan-TGF-β antibody reduced tumor burden and osteolytic lesions in a mouse model of bone metastasis [13], and overexpression of TGF-β-signaling inhibitor Smad7 in a mouse model delayed the establishment and the growth of melanoma bone metastases [14, 15].